Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: The study aimed to assess the antidepressant efficacy and tolerability of adjunctive ropinirole in outpatients with treatment-resistant depression (TRD). Method: The study sample consisted of patients with a major depressive episode (diagnosed according to DSM-IV criteria) and TRD. Ropinirole 0.25 to 1.5 mg daily was added to tricyclic antidepressants or selective serotonin reuptake inhibitors. We conducted assessments at baseline and at weeks 2, 4, 8, 12, and 16. We defined response as a 50% or greater reduction of the Montgomery–Asberg Depression Rating Scale (MADRS) total score plus a score of 1 (“very much improved”) or 2 (“much improved”) on the Clinical Global Impression of Improvement scale at endpoint. Tolerability was monitored with the Dosage Record Treatment Emergent Symptom Scale. Results: Seven patients had major depressive disorder, and 3 had bipolar II disorder. The mean maximum dose of ropinirole was 1.33 mg daily. Mean (SD) scores on the MADRS decreased from 29.6 (7.6) at baseline to 16.9 (12.1) at endpoint ( P < 0.02). At endpoint, 4 of 10 (40%) patients were responders. Two patients discontinued ropinirole because of dizziness. Conclusions: These pilot data suggest that, in selected cases of TRD, ropinirole augmentation of antidepressants is effective and relatively well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ropinirole augmentation of antidepressant treatment in a small sample of refractory patients reduced depression scores by half in 40% of patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Cassano et al., 2005
Citations
Cites
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Self-citationGoldberg, J. F., Burdick, K. E., & Endick, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.564 · Cited by 372
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347
The mesolimbic dopamine system as a target for rapid antidepressant action
Willner, P. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00002 · Cited by 208
Clinical Pharmacokinetics of Ropinirole
Kaye, C. M., & Nicholls, B. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00001 · Cited by 175
Pérez, V. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.375 · Cited by 154
Sporn, J., Ghaemi, S. N., Sambur, M. R., Rankin, M. A., Recht, J., Sachs, G. S., Rosenbaum, J. F., & Fava, M. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009060800999 · Cited by 153
Pramipexole in treatment‐resistant depression: a 16‐week naturalistic study
Lattanzi, L., Dell'Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P. R., Gemignani, A., Battistini, G., Bassi, A., Abelli, M., et al. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01171.x · Cited by 150
Self-citationEfficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
Maes, M. H. J., Vandoolaeghe, E., & Desnyder, R. (1996) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)00089-4 · Cited by 125
Sporn, J., Ghaemi, S. N., Sambur, M. R., et al. (2000) · Annals of Clinical Psychiatry · doi:10.3109/10401230009147102 · Cited by 118
Research works printed but not linked: 1
- Brooks DJ, 1998, Clin Neuropharmacol, 21, 101
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“Finally, DA agonists such as bromocriptine, ropinirole and pramipexole also exhibit antidepressant properties (Cassano et al., 2005; Corrigan et al., 2000; Sitland-Marken et al., 1990)).”
BackgroundInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Metadata
- Authors
- Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B.
- Affiliations
- Massachusetts General Hospital (US)
- University of Pisa (IT)
- Director, Depression Clinical and Research Program Massachusetts General Hospital, Boston, Massachusetts
- Corresponding author
- Cassano, Paolo
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2005-05
- Volume
- 50
- Issue
- 6
- Pages
- 357-360
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2119768046
- Cited by
- 73
- References
- 17
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 6
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ropinirole, treatment-resistant depression, adjunctive therapy, dopamine agonists, antidepressant augmentation, major depressive disorder, bipolar II disorder, tricyclic antidepressants, selective serotonin reuptake inhibitors, tolerability, dizziness
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Drug Resistance, Female, Humans, Indoles, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Dopamine Agonists, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study. https://app.cochat.ai/papers/10.1177/070674370505000612
- The paper
- Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005). Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674370505000612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.